Continuous Glucose Monitoring Market: Growth Trends, Key Players, and Regional Insights 2024-2028

The continuous glucose monitoring (Cgm) market is set to witness significant growth, with a forecasted increase of USD 2.94 billion from 2024 to 2028, driven by a 6.78% CAGR. Rising diabetes prevalence, technological advancements, and the increasing adoption of home healthcare devices fuel market expansion. As per the International Diabetes Foundation (IDF), diabetes cases are expected to reach 700 million by 2045, escalating the demand for real-time glucose monitoring solutions. The market is also benefiting from AI-powered CGM systems, miniaturization trends, and wireless technologies, enhancing accessibility and efficiency. However, high costs, stringent regulatory requirements, and data security concerns remain major challenges for stakeholders.

For more details about the industry, get the PDF sample report for free

Market Segmentation

By Component

• Sensors – The dominant segment, essential for real-time glucose tracking, was valued at USD 2.53 billion in 2018 and continues to grow due to increased demand for non-invasive diabetes management.
• Transmitters – These devices enhance communication between CGM systems and user interfaces, improving monitoring accuracy.
• Receivers – Critical for interpreting glucose levels and transmitting data to healthcare providers or mobile applications.

By End-User

• Home Care – The rising preference for at-home monitoring drives this segment, with FreeStyle Libre and Dexcom G6 leading the market.
• Hospitals – Continuous glucose monitoring adoption in hospitals ensures real-time glucose management for inpatients.
• Others – Clinics and specialty healthcare centers contribute to market expansion, particularly in emerging economies.

Regional Market

North America (50% Market Contribution)

• United States – Leading the CGM market, driven by high diabetes awareness, technological advancements, and strong regulatory approvals from the FDA.
• Canada – Increasing CGM adoption, supported by healthcare reimbursement policies and growing diabetes prevalence.

Europe

• United Kingdom – Expansion driven by NHS initiatives promoting CGM adoption for diabetic patients.
• Germany – Strong R&D investments and regulatory approvals boost market penetration.
• France – Increasing government healthcare funding supports wider CGM adoption.

Asia-Pacific

• China – Growing diabetic population fuels demand for CGM devices.
• India – Low diagnosis rates pose a challenge, but government efforts to improve diabetes management are increasing.
• Indonesia & Vietnam – Rising healthcare investments support the market's expansion.

Rest of the World

• Saudi Arabia – Government initiatives to combat rising diabetes cases bolster market growth.
• South Africa – CGM adoption is increasing due to rising obesity-related diabetes.
• Chile & Brazil – Expanding healthcare infrastructure is driving demand for advanced glucose monitoring solutions.

Key Market Dynamics

Drivers

• Diabetes Prevalence & Lifestyle Changes – Rising cases due to obesity, smoking, urbanization, and sedentary lifestyles accelerate demand.
• Technological Innovations – AI and machine learning-based glucose tracking, non-invasive CGM devices, and smartphone integration enhance usability.
• Increased Adoption of Home Healthcare Devices – Demand for self-monitoring solutions like Dexcom G7 and Abbott FreeStyle Libre 3 is rising.

Trends

• Miniaturization of CGM Devices – Wearable and implantable devices improve convenience.
• Smart CGM Systems – AI-powered real-time glucose data analytics enhance personalized healthcare.
• Strategic Collaborations – Tech companies and healthcare providers are forming alliances to refine CGM systems and expand market reach.

Challenges

• High Costs & Regulatory Compliance – Affordability and regulatory barriers restrict adoption in some regions.
• Low Diagnosis Rates in Emerging Markets – Countries like India and China struggle with undiagnosed diabetes cases exceeding 55%.
• Data Privacy Concerns – Increased use of cloud-based CGM platforms raises cybersecurity challenges.

Get more details by ordering the complete report

Key Companies in the Continuous Glucose Monitoring (Cgm) Market

Some of the key companies of the Continuous Glucose Monitoring (Cgm) Market are as follows:

• A. Menarini Industrie Farmaceutiche Riunite Srl
• Abbott Laboratories
• Ascensia Diabetes Care Holdings AG
• B.Braun SE
• Dexcom Inc.
• F. Hoffmann La Roche Ltd.
• General Electric Co.
• GlySens Inc.
• Johnson and Johnson Services Inc.
• LifeScan IP Holdings LLC
• Medtronic Plc
• Medtrum Technologies Inc.
• Novo Nordisk AS
• NXP Semiconductors NV
• Senseonics Holdings Inc.
• STMicroelectronics International N.V.
• Tandem Diabetes Care Inc.
• Terumo Corp.
• Ypsomed Holding AG

Recent Market Developments

• Dexcom G7 Launched (December 2023) – A next-generation CGM system with faster data transmission and enhanced accuracy.
• Abbott's FreeStyle Libre 3 FDA Approval (November 2023) – The smallest and most accurate CGM sensor to date.
• Medtronic and Dexcom Partnership (October 2023) – Collaboration to integrate CGM with insulin pumps.
• Senseonics Eversense E3 Launch in Europe (September 2023) – First long-term implantable CGM device receives regulatory approval.
• Novo Nordisk & Tandem Diabetes Care Collaboration (August 2023) – Focus on AI-driven diabetes management.
• NXP Semiconductors Announces AI-Based CGM Sensors (July 2023) – Enhancing real-time glucose monitoring accuracy.